Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IFNG antisense RNA 1 (IFNG-AS1)
- Target
- IFNG-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Enhancer RNA, Other (antisense RNA)
01
Overview
IFNG antisense RNA 1 (IFNG-AS1) is a long non-coding RNA located on chromosome 12q15, transcribed from the strand opposite to IFNG. It acts as a positive regulator of the interferon gamma gene (IFN-γ), primarily within T helper 1 (Th1) and natural killer (NK) cells, and promotes IFN-γ transcription through epigenetic mechanisms involving chromatin remodeling and histone modification. IFNG-AS1 expression is regulated by the transcription factors T-bet and Stat4. Aberrant IFNG-AS1 expression is linked to multiple autoimmune and infectious diseases and may function both as a biomarker and a potential therapeutic target for conditions driven by Th1/IFN-γ-mediated immune responses[1][2][3].
- Other names
- Tmevpg1NESTLincR-Ifng-3'ASTheiler’s murine encephalomyelitis virus persistence candidate gene 1nettoie Salmonella pas Theiler’sGS1-410F4.2IFNG antisense RNA 1 (non-protein coding)
02
Mechanism of action
Knockdown of IFNG-AS1 (e.g., via siRNA) reduces IFN-γ production by Th1 cells[2][3]. Upregulation of IFNG-AS1 enhances IFN-γ gene transcription and Th1 cell activity[1][2][3].
03
Biological functions
Regulation of IFN-γ (interferon gamma) gene expressionEpigenetic modulation (chromatin remodeling, histone methylation)Positive regulation of Th1 cell differentiationImmune response modulation
04
Disease associations
Autoimmune disorders (e.g., Hashimoto’s thyroiditis, childhood idiopathic thrombocytopenic purpura (ITP))Infections (e.g., brucellosis, Theiler’s virus, Salmonella enterica)Other (potential roles in inflammatory diseases)
05
Safety considerations
Not directly reported; however, therapies modulating IFNG-AS1 may alter immune function and cytokine signaling, potentially leading to immune dysregulation or increased risk of infections[3].
06
Interacting drugs
siRNA
3 more in the full profile.
07
Biomarkers
IFNG-AS1 transcript levels (as a biomarker for Th1 cell activation and autoimmune disease activity)[2][3]Correlated with increased serum anti-thyroglobulin antibody and anti-thyroperoxidase antibody (in Hashimoto’s thyroiditis)[2]
Beyond the preview
Go deeper on IFNG antisense RNA 1 (IFNG-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFNG antisense RNA 1 (IFNG-AS1).